-

12:00:07 AM

AXIM Stock News

AXIM - Axim Biotechnologies Inc

09/12/23 9:00 AM

OTC : AXIM

AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease

AXIM Biotechnologies, Inc., an international healthcare diagnostic solutions development company, announced today that it has successfully developed the world’ s first rapid, point-of-care,...

RHEA-AI

neutral

08/01/23 9:00 AM

OTC : AXIM

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test

AXIM Biotechnologies, Inc., an international healthcare diagnostic solutions development company, announced today the receipt of notification by the United States Patent& Trademark Office of several patent allowances. AXIM has been developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including, for example,...

RHEA-AI

positive

07/12/23 9:00 AM

OTC : AXIM

AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide

via NewMediaWire – AXIM Biotechnologies, Inc . ( OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international

RHEA-AI

neutral

05/24/23 9:52 AM

OTC : AXIM

AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch

via NewMediaWire – AXIM Biotechnologies, Inc . ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare

RHEA-AI

positive

05/23/23 9:00 AM

OTC : AXIM

management

AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit

AXIM Biotechnologies, Inc . ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the Company”), an

RHEA-AI

positive

04/11/23 9:00 AM

OTC : AXIM

AXIM® Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays

AXIM Biotechnologies, Inc . ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM”

RHEA-AI

neutral

03/14/23 9:00 AM

OTC : AXIM

AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing

AXIM Biotechnologies, Inc . ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the

RHEA-AI

neutral

01/17/23 1:32 PM

OTC : AXIM

AXIM Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance

AXIM Biotechnologies, Inc . ( OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an

RHEA-AI

neutral

01/11/23 9:00 AM

OTC : AXIM

AXIM® Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call

Summary:In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye disease (DED) diagnostic tests through commercialization partner Verséa Ophthalmics AXIM

RHEA-AI

positive

12/13/22 9:00 AM

OTC : AXIM

AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent

AXIM Biotechnologies, Inc . (

RHEA-AI

positive

AXIM Data

IndustryPharmaceutical Preparation Manufacturing
Security nameAxim Biotechnologies Inc
SectorManufacturing
Tags
- Environmental Services
- Industrial Services
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Axim Biotechnologies Inc

axim biotechnologies, inc. is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and sars-cov-2 (covid-19). the company's neucovix is the rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent sars-cov-2 from entering the host cells. it is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. the company was formerly known as axim international inc. and changed its name to axim biotechnologies, inc. in july 2014. axim biotechnologies, inc. was founded in 2010 and is headquartered in san diego, california.